• We are catalysts for innovation, commercialising next-generation technologies developed by

    The University of Manchester’s world-class research base





    • £360m+ invested by venture funders

    • 40+ spin-out companies created

    • 7,500+ licences and IP partnerships concluded

    • 4,000+ invention disclosures received

    • £115m+ IP and R&D revenue generated for the University







  • We are catalysts for innovation, commercialising next-generation technologies developed by The University of Manchester’s world-class research base





    • £300m+ invested by venture funders since 2004

    • 40+ spin-out companies created

    • 4,800+



      licences and IP partnerships concluded

    • 3,700+ invention disclosures received

    • 1,300+ jobs generated across various industry sectors

    • £105m+ IP and R&D revenue generated for the University


Archive for 2012

Funding opportunities from the Research Deanery

The Research Deanery welcomes applications for the following open funding opportunities. Read more below or visit the Research Deanery website for full information and application forms.

1: MRC Confidence in Concept (CiC) Award – The University of Manchester

The University of Manchester has been awarded £500k from the MRC Confidence in Concept (CiC) scheme. The University allocation will provide awards up to £100k for a duration of 6-12 months.

This is an exciting opportunity to apply for funding to gather data/support feasibility studies to feed next stage, substantial external applications from the MRC DPFS or similar initiatives from other funders or industry.

The University CiC scheme will invest in projects in the following four categories:

  • Diagnostics
  • Devices
  • Therapeutics
  • Informatics

Interdisciplinary projects are encouraged.

An Expression of Interest should be submitted to the Research Deanery RD@manchester.ac.uk by 21st December 2012. This should include just your name, position, department, Title of Proposal and which of the four categories listed above it belongs to. 

For further information and an application form click here (University login required).

Completed applications should be submitted by midnight on February 4th 2013 to: RD@manchester.ac.uk

General enquiries on this scheme to: Roz.kelly@manchester.ac.uk /0161 306 0562.

 

2: Graphene Bioscience Interdisciplinary Grand Challenges

The University of Manchester has committed £200K to pump-prime investigations into how Graphene-based solutions might be applied to biomedical/life science problems.

Applications for pilot studies (up to 12 months in duration) are encouraged from researchers across the University.

Major challenge areas for use of Graphene in life science/biomedical applications:

  • Biointegration
  • Biological barriers
  • Biosensors
  • Enzyme/material based hybrid systems
  • Selective adsorptive properties of Graphene

Although the above areas provide the main focus of this call they are not exclusive and alternative transformative ideas are also welcomed.

For further information and an application form click here (University login required).

Application process:

 Outline applications and completion of the Graphene Clinic Doodle Poll by 4pm Thursday 10th January 2013

  • Full applications by 4pm Thursday 14th February 2013

 

Please submit outline/full applications to the FMHS Research Deanery: RD@manchester.ac.uk.

General enquiries: Kay.Hodgson@manchester.ac.uk /0161 306 0552

 

3: Liverpool and Manchester MRC Confidence in Concept (CiC) Fund

£100K is available for University of Manchester and University of Liverpool collaborative projects under the MRC Liverpool and Manchester Confidence in Concept (CiC) scheme.

The funding will provide awards up to £50k for a duration of 6-12 months to be used to support the earliest stages of translational research projects. It is intended to support preliminary work or feasibility studies to establish the viability of an approach i.e. to provide confidence in the underlying concept – before seeking more substantive funding from the MRC DPFS/DCS/TSCRC or similar initiatives from other funders or Industry.

The Universities wish to exploit their untapped potential and accelerate progress in translating discovery science in areas of key strategic interest such as Cancer, Inflammation, Regenerative Medicine, Women’s health, Paediatrics, Medical Genetics, Clinical Pharmacology, Ophthalmology, Cardiovascular and Neuropsychiatric disorders and this will be achieved by using the Liverpool Manchester CiC scheme to invest in projects in the following four categories:

  • Diagnostics
  • Devices
  • Therapeutics
  • Informatics

Project funding will be up to a maximum sum of £50,000 inclusive of value added tax, with a duration of between 6–12 months, it is anticipated that the Liverpool and Manchester CiC Scheme shall be used flexibly to fund a number of individual proposals. The maximum total sum available for the Liverpool and Manchester CiC Scheme is £100,000 which, subject to successful project applications, will be equally divided between the Parties.

Projects must have a minimum of two partners, one from the University of Liverpool and one from the University of Manchester. 

Multidisciplinary project proposals are encouraged.

 

  An expression of interest should be submitted to the Research Deanery RD@manchester.ac.uk by 10th Jan 2013.

 This should include just your name, position, department, Title of Proposal and which of the four categories listed above it belongs to.  

 Completed applications should be submitted by midnight on Monday 14th February 2013 to: RD@manchester.ac.uk

 For further information and an application form click here (University login required).

 General enquiries on this scheme to: Lisa.hearty@manchester.ac.uk/0161 306 0551

 For more funding opportunities please follow the Research Deanery on Twitter

Or visit the Research Deanery website

Manchester team wins ‘Best consideration of IP strategy’ in Biotech business plan competition

Enzomax, who beat off stiff competition from 15 other teams from universities and institutes around the UK in the Biotechnology Young Entrepreneurs Scheme (Biotechnology YES) 2012 competition ihn November, have won the ‘Best consideration of IP strategy’ category, at the final held in London last night.

The annual contest, co-organised by the Biotechnology and Biological Sciences Research Council (BBSRC) and the University of Nottingham Institute for Enterprise and Innovation (UNIEI), was held at the London Marriot Hotel County Hall.

Enzomax have a proprietary platform technology, known as Enzomax SHIELD™, which they use to deliver cost-effective solutions for maximising the performance of enzymes in industrial biotechnology.

The competition, in its 17th year, sees bioscience postgraduate and postdoctoral researchers develop hypothetical business plans for plausible biotechnology companies. They receive help and advice from speakers, mentors and judges in areas such as intellectual property, financial planning and marketing.

The competition was won by a team from Cambridge University, Calvitium Solutions, who has developed a patentable hair-loss prevention product with a novel and specific mode of action, with potentially less side effects and is cheaper than the current drugs on the market.

Conformetrix CEO to discuss partnering strategies at Genesis 2012

The CEO of Conformetrix Ltd, a leader in optimising drug discovery and design, will discuss partnering strategies and the impact of deals at the One Nucleus Genesis 2012 conference in London on December 13. Dr Sam Williams will also take part in the pre-Genesis 2012 Seminar and BioNewsRound Award the day before the conference.

At the Genesis event, Dr Williams will share his insights into how to secure and manage the optimal deal. Conformetrix is a spin-out from the University of Manchester, working with companies across the sector to optimise drug discovery and design. It entered into a strategic partnership with AstraZeneca in April 2012.

Conformetrix’s NMR technology determines accurate three-dimensional structures – or conformations – of drug molecules in their bioactive states. This is achieved without the need for traditional structural information regarding the protein target of each drug, thereby providing researchers with valuable information on how development-stage compounds are likely to interact with their targets. This new information should improve the efficiency and quality of the lead identification, lead optimisation and candidate selection stages of drug discovery programmes.

www.conformetrix.com

 

Manchester wins three awards at the 2012 Northwest Bionow Awards

Over 280 people from the Northwest’s biomedical sector gathered on 29th November at the 11th Northwest Biomedical Awards at Mere Golf and Country Club, Cheshire. This prestigious awards dinner celebrates key achievements from companies and individuals who have made a significant contribution to the biomedical sector during 2012.   

The judging panel which decided the winners consisted of representatives from each of the award sponsors and considered over 60 applications.

The University of Manchester winners were:

University of Manchester spin-out, Phagenesis Ltd, Phagenyx – Healthcare Project of the Year.

University of Manchester, Microsensor – Biomedical Project of the Year.

Euprotec Ltd – Service Company of the Year
 

The complete list of winners is as follows:

Start-Up Company of the Year
Incanthera Ltd

Promising Technologist of the Year
Dr Nick Bryan, CellCap Technologies Ltd

Healthcare Project of the Year
Phagenesis Ltd, Phagenyx

Product or Service of the Year
Biofortuna Ltd, Stable Molecular Diagnostic PCR reagents

Biomedical Project of the Year
University of Manchester, Microsensor

Investment Deal of the Year
Clinigen Group Plc, Clinigen Group IPO

Service Company of the Year
Euprotec Ltd

Company of the Year
Eden Biodesign
 

For more information about Bionow, please visit www.bionow.co.uk

Graphene Bioscience Interdisciplinary Grand Challenges at The University of Manchester

Funding available: Graphene Bioscience Interdisciplinary Grand Challenges

The University of Manchester has committed £200K to pump-prime investigations into how Graphene-based solutions might be applied to biomedical/life science problems.

Applications for pilot studies (up to 12 months in duration) are encouraged from researchers across the University.

Major challenge areas for use of Graphene in life science/biomedical applications:

> Biointegration

> Biological barriers

> Biosensors

> Enzyme/material based hybrid systems

> Selective adsorptive properties of Graphene

 

Although the above areas provide the main focus of this call they are not exclusive and alternative

transformative ideas are also welcomed.

For further info on the scheme go to:  www.mhs.manchester.ac.uk/research/support/deanery

 

Application process:

Outline applications and completion of the Graphene Clinic Doodle Poll by 4pm Thursday 10th January 2013

Full applications by 4pm Thursday 14th February 2013

Please submit outline/full applications to the FMHS Research Deanery: RD@manchester.ac.uk. 

General enquiries: Kay.Hodgson@manchester.ac.uk /0161 306 0552

CONTACT US